David Charles Lubner, a director at $ACLX, sold 6,000 shares of the company on 01-20-2026 for an estimated $450,000. We received data on the trade from a recent SEC filing. This was a sale of approximately 21.7% of their shares of this class of stock. Following this trade, they now own 21,659 shares of this class of $ACLX stock.
$ACLX Insider Trading Activity
$ACLX insiders have traded $ACLX stock on the open market 15 times in the past 6 months. Of those trades, 0 have been purchases and 15 have been sales.
Here’s a breakdown of recent trading of $ACLX stock by insiders over the last 6 months:
- CHRISTOPHER HEERY (CHIEF MEDICAL OFFICER) has made 0 purchases and 11 sales selling 56,936 shares for an estimated $4,314,293.
- MICHELLE GILSON (CHIEF FINANCIAL OFFICER) has made 0 purchases and 3 sales selling 11,310 shares for an estimated $999,918.
- DAVID CHARLES LUBNER sold 6,000 shares for an estimated $450,000
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$ACLX Hedge Fund Activity
We have seen 91 institutional investors add shares of $ACLX stock to their portfolio, and 102 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- T. ROWE PRICE INVESTMENT MANAGEMENT, INC. added 4,408,630 shares (+226.8%) to their portfolio in Q3 2025, for an estimated $361,948,523
- VESTAL POINT CAPITAL, LP removed 1,500,000 shares (-54.5%) from their portfolio in Q3 2025, for an estimated $123,149,999
- CITADEL ADVISORS LLC added 823,090 shares (+414.9%) to their portfolio in Q3 2025, for an estimated $67,575,689
- NEA MANAGEMENT COMPANY, LLC removed 700,000 shares (-18.7%) from their portfolio in Q3 2025, for an estimated $57,469,999
- DECHENG CAPITAL LLC removed 547,609 shares (-100.0%) from their portfolio in Q3 2025, for an estimated $44,958,698
- DIMENSIONAL FUND ADVISORS LP removed 259,602 shares (-75.7%) from their portfolio in Q3 2025, for an estimated $21,313,324
- FMR LLC removed 210,834 shares (-3.5%) from their portfolio in Q3 2025, for an estimated $17,309,471
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
$ACLX Analyst Ratings
Wall Street analysts have issued reports on $ACLX in the last several months. We have seen 6 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- UBS issued a "Buy" rating on 01/07/2026
- Wells Fargo issued a "Overweight" rating on 12/22/2025
- Needham issued a "Buy" rating on 12/08/2025
- Canaccord Genuity issued a "Buy" rating on 11/03/2025
- Stifel issued a "Buy" rating on 10/16/2025
- Scotiabank issued a "Sector Outperform" rating on 07/31/2025
To track analyst ratings and price targets for $ACLX, check out Quiver Quantitative's $ACLX forecast page.
$ACLX Price Targets
Multiple analysts have issued price targets for $ACLX recently. We have seen 7 analysts offer price targets for $ACLX in the last 6 months, with a median target of $105.0.
Here are some recent targets:
- Michael Yee from UBS set a target price of $100.0 on 01/07/2026
- An analyst from Wells Fargo set a target price of $100.0 on 12/22/2025
- Gil Blum from Needham set a target price of $105.0 on 12/08/2025
- John Newman from Canaccord Genuity set a target price of $130.0 on 12/08/2025
- Stephen Willey from Stifel set a target price of $129.0 on 10/16/2025
- Eric Schmidt from Cantor Fitzgerald set a target price of $88.0 on 10/09/2025
- George Farmer from Scotiabank set a target price of $133.0 on 07/31/2025
This article is not financial advice. See Quiver Quantitative's disclaimers for more information.
